(RTTNews) - Shares of Co-Diagnostics, Inc. (CODX) jumped 15% on Monday morning after the company announced it received FDA's emergency use authorization for its Covid-19 test.
CODX is currently trading at $27.49, up $3.49 or 14.55%, on the Nasdaq.
Co-Diagnostics said its partner, Clinical Reference Laboratory has FDA Emergency Use Authorization for CRL Rapid Response, a saliva-based COVID-19 test that can be self-administered at home, work or any other setting and then tested using Co-Diagnostics' patented CoPrimer technology.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryCODX
Latest Markets Videos
- Stimulus Update: MIllions Will Get a Stimulus Check in June. Are You One of Them?
- Social Security Checks Could Soar in 2023: Here's How Much Extra Seniors Might Receive
- Better Buy: Dogecoin vs. Terra Classic vs. Terra (LUNA)?
- Bitcoin Uses 50 Times Less Energy Than Traditional Banking, New Study Shows